文献速递生殖医学

不明原因不孕行卵巢刺激-宫腔内人工授精中卵泡晚期孕酮提前升高对妊娠结局的影响:AMIGOS试验的二次分析

Effect of prematurely elevated late follicular progesterone on pregnancy outcomes following ovarian stimulation-intrauterine insemination for unexplained infertility: secondary analysis of the AMIGOS trial.
PubMed 文献 · Hum Reprod · 2024-01-01

该研究为AMIGOS随机对照试验的前瞻性队列二次分析,纳入828名不明原因不孕女性的2121个卵巢刺激-宫腔内人工授精周期,检测hCG触发日血清孕酮。与孕酮<1.0 ng/ml参照组相比,孕酮1.0至<1.5 ng/ml组的活产率和临床妊娠率显著升高,而孕酮≥1.5 ng/ml组与参照组无显著差异。

要点

  • 孕酮1.0至<1.5 ng/ml组活产率12.22%,高于参照组8.07%,校正RR 1.51。
  • 孕酮1.0至<1.5 ng/ml组临床妊娠率13.72%,高于参照组9.54%,校正RR 1.42。
  • 孕酮≥1.5 ng/ml组临床妊娠率和活产率与参照组无显著差异。

核心结论

  • 卵泡晚期孕酮1.0至<1.5 ng/ml与较高的活产率和临床妊娠率相关,而孕酮≥1.5 ng/ml组的结局与<1.0 ng/ml参照组无显著差异。
  • 作者认为需要进一步研究以明确该孕酮范围是否真正代表卵巢刺激-宫腔内人工授精周期的预后指标。

研究设计与样本

  • 研究为AMIGOS随机对照试验的前瞻性队列分析,纳入828名不明原因不孕参与者,共2121个周期有冻存血清可供评估。
  • 主要妊娠结局为每周期活产,次要妊娠结局为每周期临床妊娠率。
  • 采用聚类加权广义估计方程拟合改良泊松回归模型估算未校正和校正风险比(RR)及95%CI。

主要发现

  • 孕酮<1.0 ng/ml参照组活产110/1363(8.07%),孕酮1.0至<1.5 ng/ml组活产49/401(12.22%),未校正RR 1.56(95%CI 1.14, 2.13),治疗校正后RR 1.51(95%CI 1.10, 2.06)。
  • 参照组临床妊娠130/1363(9.54%),孕酮1.0至<1.5 ng/ml组临床妊娠55/401(13.72%),未校正RR 1.46(95%CI 1.10, 1.94),校正后RR 1.42(95%CI 1.07, 1.89)。
  • 孕酮1.5 ng/ml及以上周期与参照组相比,临床妊娠率和活产率无显著差异。
  • 按卵巢刺激治疗组分层后该模式仍存在,但仅在来曲唑周期中具有统计学显著性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • AMIGOS试验并非为回答该临床问题而设计,部分孕酮类别样本量小,分析效力不足以检测某些组间差异。
  • 纳入孕酮值高于3.0 ng/ml的周期可能包括在人工授精时已排卵的周期,这些周期预期成功率较低,但同一周期内性交可能已导致妊娠。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: What is the relationship between late follicular phase progesterone levels and clinic pregnancy and live birth rates in couples with unexplained infertility undergoing ovarian stimulation with IUI (OS-IUI)? SUMMARY ANSWER: Late follicular progesterone levels between 1.0 and <1.5 ng/ml were associated with higher live birth and clinical pregnancy rates while the outcomes in groups with higher progesterone levels did not differ appreciably from the <1.0 ng/ml reference group. WHAT IS KNOWN ALREADY: Elevated late follicular progesterone levels have been associated with lower live birth rates after fresh embryo transfer following controlled ovarian stimulation and egg retrieval, but less is known about whether an association exists with outcomes in OS-IUI cycles. Existing studies are few and have been limited to ovarian stimulation with gonadotrophins, but the use of oral agents, such as clomiphene citrate and letrozole, is common with these treatments and has not been well studied. STUDY DESIGN, SIZE, DURATION: The study was a prospective cohort analysis of the Assessment of Multiple Intrauterine Gestations from Ovarian Stimulation (AMIGOS) randomized controlled trial. Frozen serum was available for evaluation from 2121 cycles in 828 AMIGOS participants. The primary pregnancy outcome was live birth per cycle, and the secondary pregnancy outcome was clinical pregnancy rate per cycle. PARTICIPANTS/MATERIALS, SETTING, METHODS: Couples with unexplained infertility in the AMIGOS trial, for whom female serum from day of trigger with hCG was available in at least one cycle of treatment, were included. Stored frozen serum samples from day of hCG trigger during treatment with OS-IUI were evaluated for serum progesterone level. Progesterone level <1.0 ng/ml was the reference group for comparison with progesterone categorized in increments of 0.5 ng/ml up to ≥3.0 ng/ml. Unadjusted and adjusted risk ratios (RR) and 95% CI were estimated using cluster-weighted generalized estimating equations to estimate modified Poisson regression models with robust standard errors. MAIN RESULTS AND THE ROLE OF CHANCE: Compared to the reference group with 110/1363 live births (8.07%), live birth rates were significantly increased in cycles with progesterone 1.0 to <1.5 ng/ml (49/401 live births, 12.22%) in both the unadjusted (RR 1.56, 95% CI 1.14, 2.13) and treatment-adjusted models (RR 1.51, 95% CI 1.10, 2.06). Clinical pregnancy rates were also higher in this group (55/401 clinical pregnancies, 13.72%) compared to reference group with 130/1363 (9.54%) (unadjusted RR 1.46, 95% CI 1.10, 1.94 and adjusted RR 1.42, 95% CI 1.07, 1.89). In cycles with progesterone 1.5 ng/ml and above, there was no evidence of a difference in clinical pregnancy or live birth rates relative to the reference group. This pattern remained when stratified by ovarian stimulation treatment group but was only statistically significant in letrozole cycles. LIMITATIONS, REASONS FOR CAUTION: The AMIGOS trial was not designed to answer this clinical question, and with small numbers in some progesterone categories our analyses were underpowered to detect differences between some groups. Inclusion of cycles with progesterone values above 3.0 ng/ml may have included those wherein ovulation had already occurred at the time the IUI was performed. These cycles would be expected to experience a lower success rate but pregnancy may have occurred with intercourse in the same cycle. WIDER IMPLICATIONS OF THE FINDINGS: Compared to previous literature focusing primarily on OS-IUI cycles using gonadotrophins, these data include patients using oral agents and therefore may be generalizable to the wider population of infertility patients undergoing IUI treatments. Because live births were significantly higher when progesterone ranged from 1.0 to <1.5 ng/ml, further study is needed to clarify whether this progesterone range may truly represent a prognostic indicator in OS-IUI cycles. STUDY FUNDING/COMPETING INTEREST(S): Oklahoma Shared Clinical and Translational Resources (U54GM104938) National Institute of General Medical Sciences (NIGMS). AMIGOS was funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development: U10 HD077680, U10 HD39005, U10 HD38992, U10 HD27049, U10 HD38998, U10 HD055942, HD055944, U10 HD055936, and U10HD055925. Research made possible by the funding by American Recovery and Reinvestment Act. Dr Burks has disclosed that she is a member of the Board of Directors of the Pacific Coast Reproductive Society. Dr Hansen has disclosed that he is the recipient of NIH grants unrelated to the present work, and contracts with Ferring International Pharmascience Center US and with May Health unrelated to the present work, as well as consulting fees with May Health also unrelated to the present work. Dr Diamond has disclosed that he is a stockholder and a member of the Board of Directors of Advanced Reproductive Care, Inc., and that he has a patent pending for the administration of progesterone to trigger ovulation. Dr Anderson, Dr Gavrizi, and Dr Peck do not have conflicts of interest to disclose. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Burks HR, Peck JD, Gavrizi S, et al. Effect of prematurely elevated late follicular progesterone on pregnancy outcomes following ovarian stimulation-intrauterine insemination for unexplained infertility: secondary analysis of the AMIGOS trial. Hum Reprod. 2024. PMID: 38822675. doi:10.1093/humrep/deae113

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。